REVIEW article
Front. Microbiol.
Sec. Virology
Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1666167
This article is part of the Research TopicEffective Therapeutic Strategies, Including Treatments, Vaccines, and Immunotherapies, for Combating Zoonotic Viruses and Improving Global Health OutcomesView all 5 articles
Study progress and strategy of anti-highly virulent porcine epidemic diarrhea virus vaccine and target drugs
Provisionally accepted
- Jilin Agricultural University, Changchun, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
As an acute and highly contagious enteric disease of swine, porcine epidemic diarrhea virus (PEDV) had caused high piglet mortality and significant economic losses. The commercialized vaccines only can provide partial cross-protection in againsting the novel highly virulent PEDV strains. To develop new anti-highly virulent PEDV vaccines, it will benefit to protect the pig industry from seriously challenge of the novel highly virulent PEDV infection . Natural compounds, chemical, biochemical source target drugs targeted on specially protein and enzyme or special mechanism can complement each other's advantages by drug combination that will promote the drug prevention efficiency in highly virulent PEDV controlling. Targeted on toll like receptor 3(TLR3) drugs will aid vaccine to compensate for interferon (IFN) secretory deficiency to protect pigs from highly virulent PEDV infection. The review had generalized the study progress in anti-highly virulent PEDV vaccines, natural compound, chemical and biochemical source target drugs which had been explored in cells or pigs with clearly mechanism and attempted to provide extensive strategy in prevention and controlling highly virulent pigs PEDV infection with pigs recently.
Keywords: Porcine epidemic diarrhea virus, anti-virus, Vaccine, drug, toll like receptors 3
Received: 15 Jul 2025; Accepted: 22 Sep 2025.
Copyright: © 2025 Wang, Chen, Liu, Xuanyi, Zhang, Wang, Dong and Qingfeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Qiuxuan Wang, 820562596@qq.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.